Monday 13/April/2026 – 05:18 AM
The results of a recent clinical trial revealed a new glimmer of hope for patients with ovarian tumors, after a drug already used to treat a rare disease showed a remarkable ability to prolong the lives of those affected, and reduce the risk of death by up to 35%, according to The Sun.
A new drug gives hope to ovarian tumor patients and reduces deaths by 35%
The study showed that the drug “Relacorilant”, used to treat Cushing’s syndrome, can make a big difference when added to traditional chemotherapy, especially in women with ovarian cancer resistant to platinum therapy, which is one of the most difficult types to treat.
The study included 381 patients, one group of whom was given a combination of “relacurilant” with the drug “nab-paclitaxel,” while the other group received only the usual treatment. The results showed that the average survival increased to 16 months in the first group, compared to 11.9 months in the others, an increase of about 4 months.
The researchers stressed that this improvement is an important step, especially since patients with this type of cancer often do not live more than a year after diagnosis.
Additional advantages of the new treatment
In addition to its effectiveness, the drug can be taken at home, with fewer side effects compared to traditional treatments, making it a convenient option for patients. Experts believe that this treatment may become a new standard in dealing with advanced and recurrent cases of ovarian cancer.
The US Food and Drug Administration recently approved the use of this therapeutic combination, while some health authorities in other countries are still studying its approval.
Ovarian cancer is a disease that is difficult to detect early due to its non-specific symptoms, such as bloating, abdominal pain, loss of appetite, and frequent urination. It is often diagnosed in the late stages, which reduces the chances of treatment.
